Is retatrutide approved after TRIUMPH-1?

No. It remains investigational worldwide. Lilly has signalled an FDA filing in Q1 2027, and filing is the start of a review, not the end of one.

How does 28.3% compare with tirzepatide?

It is higher than the reductions reported in tirzepatide's pivotal obesity trials, which is the reason TRIUMPH-1 drew the attention it did.

Why does the 104-week figure only cover BMI ≥35?

The 30.3% figure comes from the extension subset with that baseline characteristic, so it is not directly comparable with the full-population 80-week result.

Research & Regulatory News

Retatrutide TRIUMPH-1: The Phase 3 Results

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-223 cited sources

TRIUMPH-1 (NCT05929066) reported topline results on 21 May 2026. Across 2,339 randomised adults, mean weight reduction at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, against 2.2% on placebo. A 104-week extension reported 30.3% mean reduction on 12 mg among participants with baseline BMI of 35 or above.

Key facts

Trial: TRIUMPH-1 (NCT05929066)
Topline reported: 21 May 2026
Randomised: 2,339 adults
Primary duration: 80 weeks
Extension: 104 weeks, 532 participants
Best mean reduction: 28.3% at 80 wks (12 mg)
Extension result: 30.3% at 104 wks (12 mg, BMI ≥35)
Regulatory status: Still investigational — no authorisation anywhere

Trial design

TRIUMPH-1 is the pivotal obesity study in Eli Lilly's Phase 3 programme for retatrutide, registered as NCT05929066. It randomised 2,339 adults across three active dose arms and placebo, with a primary analysis at 80 weeks and a continuing extension to 104 weeks in a subset of 532 participants. The programme as a whole has enrolled more than 5,800 people.

Weight reduction by dose arm

Mean reductions at 80 weeks were 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, compared with 2.2% on placebo. The dose-response relationship is clean and monotonic across the three arms, which is one of the reasons the result was treated as robust rather than a single striking headline number.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Threshold analyses

On the 12 mg arm, 62.5% of participants achieved at least 25% reduction, 45.3% achieved at least 30%, and 27.2% achieved at least 35%. Additionally 65.3% reached a BMI below 30. The 30% threshold attracted the most comment because reductions of that magnitude had previously been associated with bariatric surgery rather than pharmacotherapy.

≥25% reduction — 62.5% of participants (12 mg)
≥30% reduction — 45.3% of participants (12 mg)
≥35% reduction — 27.2% of participants (12 mg)
BMI below 30 achieved — 65.3% of participants (12 mg)

Adverse events

The safety profile was consistent with the incretin class and dominated by gastrointestinal events. Nausea was reported by 42.4% on 12 mg against 14.8% on placebo, and diarrhoea by 32.0% against 13.5%. Discontinuation due to adverse events occurred in 11.3% of the 12 mg arm against 4.9% on placebo — a meaningful figure, and one that is frequently omitted when these results are summarised.

What it does not mean

Retatrutide remains investigational. It holds no marketing authorisation from the MHRA, the EMA or the FDA, and a positive pivotal trial does not change that. Lilly has indicated it intends to file with the FDA in the first quarter of 2027. The dose arms above describe a registered clinical trial conducted under medical supervision; they are reported here as trial facts and are not handling guidance for anything.

Quick reference

Arm	Mean reduction (80 wks)	Absolute
Placebo	2.2%	5.5 lbs
4 mg	19.0%	47.2 lbs
9 mg	25.9%	64.4 lbs
12 mg	28.3%	70.3 lbs

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is retatrutide approved after TRIUMPH-1?: No. It remains investigational worldwide. Lilly has signalled an FDA filing in Q1 2027, and filing is the start of a review, not the end of one.
How does 28.3% compare with tirzepatide?: It is higher than the reductions reported in tirzepatide's pivotal obesity trials, which is the reason TRIUMPH-1 drew the attention it did.
Why does the 104-week figure only cover BMI ≥35?: The 30.3% figure comes from the extension subset with that baseline characteristic, so it is not directly comparable with the full-population 80-week result.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum